Business Context and Reporting Period
This Form 8-K was filed by Eton Pharmaceuticals, Inc. on June 14, 2024. The report discloses a change in the Company's independent registered public accounting firm. The Company is incorporated in Delaware and its common stock trades on the NASDAQ Global Market under the symbol "ETON."
Key Financial Metrics
This filing is a current report regarding a corporate governance event and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Resignation of Prior Auditor: KMJ Corbin & Company LLP ("KMJ") resigned as the Company's independent registered public accounting firm effective June 14, 2024.
- Reason for Change: The partners and professional staff of KMJ joined Crowe LLP ("Crowe") effective May 20, 2024, necessitating the change in the Company's auditor.
- Appointment of New Auditor: Following KMJ's resignation, the Company's Audit Committee approved the appointment of Crowe LLP as the new independent registered public accounting firm on June 14, 2024.
Management Commentary, Risks, and Contingencies
Audit Opinions and Disagreements: The reports issued by KMJ for the fiscal years ended December 31, 2023, and 2022 were unqualified and did not contain any adverse opinions, disclaimers, or modifications regarding uncertainty, audit scope, or accounting principles.
Disagreements and Reportable Events: The Company confirmed there were no disagreements with KMJ on accounting principles, practices, financial statement disclosures, or auditing scope/procedures during the two most recent fiscal years and the subsequent interim period. Additionally, no "reportable events" as defined in Regulation S-K occurred during this timeframe.
Consultations with New Auditor: Neither the Company nor its representatives consulted with Crowe regarding the application of accounting principles to specified transactions or matters that were subjects of disagreement or reportable events prior to Crowe's appointment.
Investor Verification Checklist
- Verify the transition timeline between KMJ Corbin & Company LLP and Crowe LLP to ensure continuity in audit oversight.
- Review the letter from KMJ (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the absence of disagreements.
- Monitor future filings (e.g., 10-K or 10-Q) for the first audit report issued by Crowe LLP to assess any changes in audit scope or findings.
- Confirm that the change in auditor was not triggered by any undisclosed financial irregularities, as explicitly stated in the filing.